ArticleBreast cancer (Tokyo, Japan)2019

CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy.

Eriko Tokunaga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.